Lifeboat Foundation

The number of people who believe—based on data, not faith—that humans can become (almost) immortal is growing, and includes the likes of scientists, billionaires, engineers and billionaire-engineers. For instance, investor Peter Thiel has donated to the anti-ageing cause, in addition to the $500,000 (around ₹3.2 crore) Palo Alto Longevity Prize for anyone who can radically extend the life of a mammal. Larry Ellison, the co-founder of Oracle, too has donated $335 million to scientists studying ageing before he decided to redirect his foundation’s grants toward eliminating polio in 2013.

When, in the future, expensive baubles cease to hold the same novelty they do today, redefined concepts of luxury are what the super-rich can pick from.

Continue reading “The new frontiers of indulgence” »

Healthy aging what does it even mean? bigsmile

#CrowdfundTheCure for #aging at www.lifespan.io

Recorded Oct 4th, 2017

Link to the interview, goo.gl/8rQ6YS

Continue reading “Aubrey de Grey — Our Moral Obligation to Cure Aging” »

We are doing a series of articles that discuss the Hallmarks of Aging. Published in 2013, this paper is highly regarded in academia and is one of the most cited papers in biology, with an average of being cited once every two days. The paper divides aging into distinct categories (“hallmarks”) of damage to explain how the aging process works and how it causes age-related diseases[1].

Today, we will be looking at one of the primary hallmarks, genomic instability.

They made their money by harnessing tech to transform life. Now, they want to use their wealth to extend the limits of life. Longevity is the new frontier for these Silicon Valley barons and they hope to again do what they do best, transform life as we know it and make a killing off it.

Recorded Oct 4th, 2017

Link to the interview, goo.gl/8rQ6YS

Continue reading “Aubrey de Grey, Ph.D.: Rejuvenation biotechnology: Why Age May Soon Not Mean Aging” »

We want to hear your story too! https://www.leafscience.org/longevity-month-2017-tell-us-your-story/

The work, published in the March 8 issue of Science, finally proves that a single anti-aging enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans.

The paper shows all of the 117 drugs tested work on the single enzyme through a common mechanism. This means that a whole new class of anti-aging drugs is now viable, which could ultimately prevent cancer, Alzheimer’s disease and type 2 diabetes.

“Ultimately, these drugs would treat one disease, but unlike drugs of today, they would prevent 20 others,” says the lead author of the paper, Professor David Sinclair, from UNSW Medicine, who is based at Harvard University. “In effect, they would slow aging.”

Continue reading “Anti-aging drug breakthrough” »